Betta Pharmaceutical announced that the company has received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the clinical trial application for extractinib hydrochloride tablets for the adjuvant treatment of IA2 high-risk stage IB non-small cell lung cancer with EGFR gene sensitive mutations after surgery has been approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.